Literature DB >> 12713620

Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.

T Baqai1, S Shousha.   

Abstract

AIMS: To compare the morphological and immunohistochemical characteristics of oestrogen receptor (ER)-negative and ER-positive ductal carcinoma in situ (DCIS) of the breast, in an attempt to establish more objective criteria for the classification of DCIS. METHODS AND
RESULTS: Sections of 64 cases of in-situ carcinoma of the breast were stained for ER, progesterone receptors (PgR), androgen receptors (AR), c-erbB-2 and p53, using the immunoperoxidase technique. The cases included 60 DCIS and four lobular carcinoma in situ (LCIS). Four DCIS lesions were associated with foci of microinvasion. The 60 DCIS cases included 31 high grade, 23 intermediate grade and six low grade. Twenty-four DCIS cases (40%) were ER-negative and 36 were positive. ER negativity was significantly associated with high nuclear grade (88% versus 27% for ER-positive cases, P < 0.001), PgR negativity (100% versus 25%, P < 0.001), c-erbB-2 positivity (79% versus 14%, P < 0.001) and p53 positivity (58% versus 6%, P < 0.001). There was no difference between ER-negative and -positive DCIS as regards AR expression, with 91% of cases in each group being AR-positive. Of the four cases of DCIS with microinvasion, three were ER- and PgR-negative, all four were c-erbB-2-positive and AR-positive and one was p53-positive. None of the four LCIS was ER, PgR or AR-negative and none was c-erbB-2- or p53-positive.
CONCLUSIONS: There is a highly significant direct relationship between ER negativity in DCIS and high nuclear grade, PgR negativity and c-erbB-2 and p53 positivity. We suggest that immunohistological assessment of ER status may help in providing a more objective way of classifying DCIS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713620     DOI: 10.1046/j.1365-2559.2003.01612.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

Review 1.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

2.  Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics.

Authors:  Elena Garre; Anna Gustafsson; Maria Carmen Leiva; Joakim Håkansson; Anders Ståhlberg; Anikó Kovács; Göran Landberg
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

3.  Radiopathological features predictive of involved margins in ductal carcinoma in situ.

Authors:  D M Layfield; H See; M Stahnke; L Hayward; R I Cutress; R S Oeppen
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

4.  Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.

Authors:  Cheng-Jun Zhou; Qing-Hui Zhang; Ting-Guo Zhang; Shan-Zhen Sun; Hong Li; Yan Wang; Zhi-Yan Liu
Journal:  Pathol Oncol Res       Date:  2008-10-22       Impact factor: 3.201

5.  Ductal carcinoma in situ: recent advances and future prospects.

Authors:  Kelly Lambert; Neill Patani; Kefah Mokbel
Journal:  Int J Surg Oncol       Date:  2012-05-17

6.  Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes.

Authors:  Qi Wu; Juanjuan Li; Si Sun; Shan Zhu; Chuang Chen; Juan Wu; Qian Liu; Wen Wei; Shengrong Sun
Journal:  Oncotarget       Date:  2017-01-10

7.  Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment.

Authors:  Yufei Liu; Kangquan Shou; Juanjuan Li; Qi Wu; Yuchang Hu; Junjie Wang; Chunyu Cao; Qing Wang
Journal:  Biomed Res Int       Date:  2020-05-27       Impact factor: 3.411

8.  Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.

Authors:  Matteo Lazzeroni; Aliana Guerrieri-Gonzaga; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Chiara Casadio; Costantino Jemos; Maria Pizzamiglio; Laura Cortesi; Davide Radice; Bernardo Bonanni
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

9.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast.

Authors:  P Meijnen; J L Peterse; N Antonini; E J Th Rutgers; M J van de Vijver
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.